PPDC announces seed grants to develop medical devices for children

The Pennsylvania Pediatric Medical Device Consortium (PPDC) has announced its latest round of seed grants to companies developing medical devices for children. The Consortium chose four companies from 11 finalists in a competition to receive seed grants of $50,000 each.

The devices are a rapid platelet monitoring system for newborns, a tracheostomy tube dislodgement alarm, and a novel electrically based intravenous catheter insertion system, and a negative pressure noninvasive ventilator for newborn intensive care.

Funded by the U.S. Food and Drug Administration and based at Children's Hospital of Philadelphia (CHOP), the PPDC provides know-how and seed funding to help innovators translate promising ideas into commercial medical devices for use in children. The PPDC is a collaboration involving CHOP, the McGowan Institute for Regenerative Medicine and sciVelo, both of the University of Pittsburgh, Drexel University, and the University of Pennsylvania.

The new round of awards is the sixth by the PPDC, following seed grants announced in February 2015, January 2016, January 2017, October 2017, and July 2018.

"This year's sponsored project competition attracted the highest number of applications ever submitted to the PPDC," said cardiologist Robert J. Levy, MD, of Children's Hospital of Philadelphia, the Consortium's Principal Investigator. "These pediatric medical devices chosen for PPDC support have great promise."

FloBio, LLC of Philadelphia is developing a novel, point-of-care microfluidic chip and reader for rapid platelet function testing. Using minimal amounts of blood, the device will monitor anticoagulation pharmacology used in newborns undergoing corrective heart surgery or on life-sustaining circulatory or pulmonary support. The device will help to control thromboembolic events in infants and children suffering from congenital heart defects.

Innovations Unlimited, LLC of Pennsauken, N.J. is creating the TrachAlarm™ to alert pediatric caregivers in a home care or other non-hospital setting if a patient's tracheostomy tube becomes dislodged. Tracheostomy tubes allow patients to breathe while undergoing treatment for certain chronic and congenital diseases. Fast recognition of tracheal dislodgement reduces risk for complications such as hypoxia, respiratory failure, cardiac arrest, and death.

The University of Pittsburgh is developing the ThreadRiteIV Catheter to improve the placement of peripheral intravenous catheters. These catheters are widely used for drug delivery in healthcare, but often require multiple attempts for insertion. ThreadRite detects blood vessels through a sophisticated system that measures differences in electrical resistance, and instantaneously alerts the operator of vessel entry via a light, audible, and vibratory signal. This eliminates the dependence on blood return for confirmation of insertion.

William J Weiss, PhD, of Penn State College of Medicine is leading efforts to develop the ThoraciCair to reduce the need for invasive and other labor-intensive techniques to treat respiratory distress syndrome in children. The ThoraciCair technology consists of a wearable device to move the chest wall and ventilate the patient by externally applying negative pressure. The ThoraciCair method creates a unique and novel platform for noninvasive ventilation strategies.

Applications for PPDC funding opportunities are accepted from throughout the U.S. and from foreign companies. The Consortium also accepts applications year-round for in-kind services and expert advice.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals underuse of antivirals for children hospitalized with influenza